About Michigan Health & Hospital Association
Michigan Health & Hospital Association (MHA) represents all of Michigan’s community hospitals. The MHA addresses key issues in the legislative and regulatory arenas to advance initiatives that protect quality, cost-effective and accessible care.
Latest Michigan Health & Hospital Association News
May 18, 2023
May 18, 2023 03:36 PM Groups representing hospitals and doctors in Michigan are warning about a shortage of two cancer drugs that can affect how patients are treated. The Michigan Health & Hospital Association and Michigan State Medical Society say manufacturing delays at several pharmaceutical companies have caused nationwide shortages of the chemotherapy drugs cisplatin and carboplatin that treat several types of cancer, including bladder, lung, ovarian and testicular cancers. The shortage for both drugs "is widespread across the country, impacting hospitals throughout all regions of Michigan," according to the Health & Hospital Association. "The priority of hospitals is delivering the right care to every patient, every time," MHA CEO Brian Peters said in a statement. "Drug shortages severely hamper a hospital's ability to provide patients with the best treatment, while forcing hospitals to implement strategies that may increase the cost of care and sometimes do not offer the same effectiveness in treatment." The MHA said the cisplatin shortage was first reported to the U.S. Food and Drug Association in February, followed by carboplatin in April. The association expects shortages for both drugs to last at least until June. To ease the situation, the MHA advocates having health insurers ease prior authorization requirements so care providers can more readily use alternative therapies, creating an early warning system to minimize the effects of shortages, and removing "regulatory obstacles" to mitigate shortages and allow drug imports. The MHA also wants to see incentives for drug makers "to stay in, re-enter or initially enter the market" and increased transparency on the cause of shortages and communication to care providers when a shortage occurs. The MHA said in a statement Wednesday that hospitals in the state "are trying many different solutions, including managing existing supply, seeking alternative sources for drugs in short supply, adjusting chemotherapy regimens for impacted patients and working with healthcare systems, as well as state and federal officials, to mitigate these challenges." A representative for the pharmaceutical industry trade association told state lawmakers Thursday morning that drug shortages are often the result of problems at manufacturing facilities. "And that's all FDA. They inspect our facilities. If there's something as mundane as a conveyor belt is not properly working, they'll shut down the plant and it's happened before," Peter Fotos, deputy vice president for state advocacy at PhRMA, or the Pharmaceutical Research and Manufacturers of America, said during a presentation to the House Insurance and Financial Services Committee. "If an exhaust fan is not working correctly, it shuts down the plant and that creates the shortage a lot of the times," Fotos said. Fotos, in his presentation about the industry to state lawmakers, did not directly address the present shortage of the two cancer drugs when asked about shortages. He said industry regularly asks the FDA about fast-tracking inspections for production facilities, "but it's a matter of manpower." "There's a ton of facilities worldwide and they're checking out facilities everywhere in the world, not just the United States," he said. Michigan State Medical Society President Dr. Salim Siddiqui said the cisplatin and carboplatin shortage "is reaching a tipping point with each passing day, casting a dark shadow over cancer treatment nationwide." "As confirmed by the United States Food and Drug administration, this crisis has already begun wreaking havoc on cancer centers throughout the country and is expected to last many months. Regrettably, Michigan, too, stands vulnerable to the dire consequences that will befall our cancer patients unless immediate measures are taken to enhance drug availability," Siddiqui said in a statement. The Medical Society urges similar steps to what the Michigan Health & Hospital Association advocates to address drug shortages, as well as a "comprehensive coordinated effort to address not only the current drug shortage but also the underlying systemic issues that contribute to such crises," Siddiqui said. "It is imperative to gain a more profound understanding of the intricate drug supply chain, comprehensively evaluating every step from raw material sourcing to production quality," he said. "Manufacturers should be encouraged to demonstrate greater transparency, sharing vital information about their processes and supply sources, ultimately fostering a more robust and resilient drug supply system." The American Cancer Society last week warned that the chemotherapy drug shortages "has become a serious and life-threatening issue for cancer patients across the country." "Like other health care organizations across the country, we are experiencing a critical shortage of commonly used chemotherapy drugs. We recognize the importance of these drugs for our patients and their loved ones and are working diligently to source these medications to meet our patients' needs," Corewell Health said Thursday in a statement to Crain's Grand Rapids Business. ByMark Sanchez, Crain's Grand Rapids Business
Michigan Health & Hospital Association Frequently Asked Questions (FAQ)
When was Michigan Health & Hospital Association founded?
Michigan Health & Hospital Association was founded in 1919.
Where is Michigan Health & Hospital Association's headquarters?
Michigan Health & Hospital Association's headquarters is located at 2112 University Park Drive, Okemos.